And when the drug was used as a prophylactic, annualized bleeding rates were between 1.38 and 2.95 episodes per year compared to 17.69 for the group that only used the drug as a treatment. The drug replaces a deficiency of Factor IX protein that occurs in patients with hemophilia B.
FULL ARTICLE AT The Motley Fool